Patient-derived tumor xenograft (PDX) model testing delivers rigorous quality control, molecular characterization, and histopathological verification that confirm the fidelity and stability of human tumor models across serial passages in immunodeficient mice. Our comprehensive testing platform integrates pathology, genomics, and biomarker analysis to support oncology drug development, biomarker discovery, and precision medicine research with clinically relevant in vivo models.
Technical Overview
Patient-derived tumor xenograft (PDX) models are established by directly transplanting fresh human tumor tissue or cells into immunodeficient mice such as NOD/SCID, NSG, or nude mice. Unlike traditional cell line-derived xenografts, PDX models preserve the histological architecture, cellular heterogeneity, stromal interactions, and molecular signatures of the original patient tumor, making them highly valuable tools for translational oncology research and preclinical drug evaluation.
Systematic testing of PDX models is essential to ensure that each model faithfully recapitulates the parental tumor and remains genetically stable throughout engraftment, expansion, and experimental use. Testing typically covers human origin authentication, histopathological consistency, molecular and biomarker concordance, microbiological safety, and in vivo growth characteristics. Quality-verified PDX models provide more reliable predictions of clinical drug response and are widely used in efficacy studies, biomarker validation, and co-clinical trials.
Testing Samples
Fresh Patient Tumor Specimens
Surgically resected primary tumors, metastatic lesions, and core needle biopsy samples collected under standardized conditions with appropriate ethical approval and informed consent. These specimens serve as the reference material against which established PDX models are compared.
PDX Tumor Tissues
Tumor tissues harvested from mice at different engraftment stages, including first-generation (P0) tumors obtained directly from patient tissue and subsequent passage generations (P1, P2, and beyond). Both fresh and cryopreserved tissue fragments can be submitted for analysis.
Malignant Effusion-Derived Samples
Tumor cells isolated from ascites and pleural effusions of cancer patients, which are commonly used to establish effusion-derived PDX models, particularly for ovarian, gastric, breast, and lung cancers.
Cryopreserved Tumor Banks
Frozen tumor fragments, viable cell suspensions, and formalin-fixed paraffin-embedded (FFPE) blocks maintained in model repositories, requiring periodic authentication, viability verification, and stability monitoring.
Mouse-Derived Biological Fluids
Blood, serum, and plasma samples collected from PDX-bearing mice for monitoring circulating human tumor markers, cytokines, and host responses during model development and drug testing.
Testing Items
Comprehensive PDX model testing encompasses the following core items:
- Human origin authentication and species composition analysis (quantification of human versus mouse cellular components)
- Short tandem repeat (STR) profiling and DNA fingerprinting for donor-to-passage matching
- Histopathological verification, including H&E morphology review and tumor type confirmation by certified pathologists
- Immunohistochemical biomarker panel testing, including Ki-67, p53, HER2, ER, PR, ALK, EGFR, and PD-L1
- Molecular profiling covering hotspot mutations, copy number variations, gene fusions, microsatellite instability, and tumor mutational burden
- Gene expression and transcriptome analysis for molecular subtyping
- Tumor purity, viability, and necrosis assessment
- Mycoplasma detection and adventitious pathogen screening
- Growth characterization, including engraftment rate, tumor latency, doubling time, and growth curve profiling
- In vivo drug response evaluation, including tumor growth inhibition, time to progression, and survival analysis
- Serum tumor marker detection, such as CEA, AFP, CA125, CA19-9, and PSA
Testing Methods
A variety of validated analytical platforms are employed depending on the testing objective:
- Hematoxylin and eosin (H&E) staining combined with expert pathological review for morphological assessment
- Immunohistochemistry (IHC) and multiplex immunofluorescence for protein biomarker detection and localization
- Polymerase chain reaction (PCR) and quantitative real-time PCR (qPCR) for mycoplasma detection, species identification, and gene expression quantification
- Next-generation sequencing (NGS), including targeted gene panels and whole-exome sequencing, for comprehensive genomic characterization
- Sanger sequencing and droplet digital PCR (ddPCR) for confirmation of specific mutations and low-frequency variant detection
- STR analysis using capillary electrophoresis for precise human identity verification
- Western blotting for protein expression validation
- Flow cytometry for quantifying human tumor cell content and analyzing cell population composition
- Enzyme-linked immunosorbent assay (ELISA) and multiplex immunoassays for serum biomarker measurement
- Standardized in vivo pharmacodynamic evaluation with tumor volume measurement and statistical analysis
Applications
PDX model testing supports a wide range of oncology research and drug development applications:
- Preclinical efficacy evaluation of novel antitumor agents, including cytotoxic drugs, targeted therapies, and antibody-based therapeutics
- Biomarker discovery and validation for patient stratification and companion diagnostic development
- Co-clinical trials that parallel patient trials to accelerate translational insights
- Personalized medicine programs guiding individualized treatment decisions
- Drug resistance mechanism studies through resistant PDX model development and characterization
- Combination therapy optimization and dosing schedule design
- Pharmacodynamic biomarker analysis to confirm target engagement
- Large-scale PDX biobank construction with authenticated, well-characterized models
FAQ
Why is testing necessary for PDX models?
Testing verifies that a PDX model maintains human origin, histological fidelity, and molecular concordance with the original patient tumor. Without routine testing, models may undergo genetic drift, lose heterogeneity, or become contaminated, compromising the reliability of downstream study results.
At which passages should PDX models be tested?
Authentication and characterization are recommended at initial establishment (P0 to P2), before banking and distribution, and periodically during serial passaging, typically every five to ten generations. Additional testing is advised before initiating critical drug efficacy experiments.
How much tumor tissue is required for testing?
For histology and DNA-based assays, approximately 20 to 50 milligrams of tissue or several FFPE sections are usually sufficient. Specific requirements vary by assay type, and the testing laboratory can provide tailored guidance based on the requested test menu.
Can PDX models change over serial passages?
Yes. Although PDX models are more stable than cell line xenografts, extended passaging can introduce genetic drift, selective outgrowth of aggressive subclones, and gradual replacement of human stromal cells with murine stroma. Systematic passage monitoring minimizes these risks and defines the recommended usage window for each model.
What is the typical turnaround time?
Histopathology and IHC results are generally available within 3 to 7 working days, mycoplasma and PCR-based assays within 3 to 5 working days, and comprehensive NGS-based molecular profiling within 2 to 4 weeks, depending on sample volume and project complexity.
How are testing results reported?
Each project is delivered with a detailed technical report including raw data, quality control metrics, comparative analysis against the parental tumor, and professional interpretation, ensuring that results are directly applicable to model qualification and study design decisions.
